Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma.

Date publication

janvier 2025

Journal

The British journal of dermatology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr AMARAL Teresa Maria

Tous les auteurs :
McGillivray E, Ashouri K, Chatziioannou E, Gallegos JAO, Zarka J, Kechter J, Hwang AS, Zhang K, Barros M, Yeh J, Okazaki I, Crocker AB, Maeda T, Park SJ, Choi J, Andreoli M, Darwish T, Savage DJ, Kim KB, Gupta J, Shen J, Shirai K, Choi A, Pai L, Vazquez VL, Moser J, Amaral T, Hernandez Aya LF, Lutzky J, Najjar YG, Costello CM, Mangold AR, Bhatia S, Gibney GT, Farma JM, Daniels GA, Sosman J, Chandra S, Mangla A, Bollin K, Possik PA, Robles-Espinoza CD, Ito F, In GK

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39438074

Résumé

Combination immune checkpoint blockade targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) leads to high response rates and improved survival in patients with advanced cutaneous melanoma (CM). Less is known about the efficacy of this combination in acral lentiginous melanoma (ALM).

Mots clés

Humans, Female, Male, CTLA-4 Antigen, antagonists & inhibitors, Programmed Cell Death 1 Receptor, antagonists & inhibitors, Retrospective Studies, Middle Aged, Skin Neoplasms, drug therapy, Aged, Melanoma, drug therapy, Immune Checkpoint Inhibitors, administration & dosage, Adult, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Progression-Free Survival, Treatment Outcome, Young Adult

Référence

Br J Dermatol. 2025 01 24;192(2):316-326